Description: EyePoint Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, engages in developing and commercializing therapeutics to improve the lives of patients with serious retinal diseases. The company's pipeline leverages its proprietary bioerodible Durasert E technology for sustained intraocular drug delivery. Its lead product candidate is EYP-1901, an investigational sustained delivery treatment for VEGF-mediated retinal diseases combining vorolanib, a selective and patent-protected tyrosine kinase inhibitor with Durasert E which is in Phase 2 clinical trials for wet age-related macular degeneration (wet AMD), non-proliferative diabetic retinopathy (NPDR), and diabetic macular edema (DME). The company's pipeline programs also include EYP-2301, a promising TIE-2 agonist formulated in Durasert E to potentially improve outcomes in serious retinal diseases. The company was formerly known as pSivida Corp. and changed its name to EyePoint Pharmaceuticals, Inc. in March 2018. EyePoint Pharmaceuticals, Inc. was incorporated in 1987 and is headquartered in Watertown, Massachusetts.
Home Page: eyepointpharma.com
480 Pleasant Street
Watertown,
MA
02472
United States
Phone:
617 926 5000
Officers
| Name | Title |
|---|---|
| Dr. Jay S. Duker M.D. | President, CEO & Director |
| Mr. George O. Elston CPA | Executive VP & CFO |
| Dr. John B. Landis M.S., Ph.D. | Interim Head of R&D and Director |
| Mr. Michael J. Maciocio | Senior Vice President of Manufacturing & Operations |
| Mr. Ron I. Honig Esq. | Chief Legal Officer & Company Secretary |
| Ms. Jennifer Leonard | Chief People Officer & Senior VP of IT |
| Mr. David Scott Jones M.A. | Senior VP & Chief Commercial Officer |
| Mr. Michael Pine | Chief Business Officer |
| Ms. Isabelle Lefebvre | Chief Regulatory Officer |
| Dr. Marcia Sellos-Moura Ph.D. | Senior VP and Head of Development & Program Management |
Exchange: F
Country: DE : Germany
Currency: Euro (€)
| GIC Sector: | Health Care |
|---|---|
| GIC Group: | Pharmaceuticals, Biotechnology & Life Sciences |
| GIC Industry: | Biotechnology |
| GIC Sub-Industry: | Biotechnology |
| Forward PE: | 0 |
|---|---|
| Trailing PE: | 0 |
| Price-to-Book MRQ: | 2.5479 |
| Price-to-Sales TTM: | 11.5897 |
| IPO Date: | |
| Fiscal Year End: | December |
| Full Time Employees: | 121 |